Effects of Antenatal Betamethasone and Dexamethasone in Preterm Neonates  by Chen, Chen-Yu et al.
Antenatal Betamethasone and Dexamethasone in Preterm Neonates
247Taiwanese J Obstet Gynecol • September 2005 • Vol 44 • No 3
EFFECTS OF ANTENATAL BETAMETHASONE AND
DEXAMETHASONE IN PRETERM NEONATES
Chen-Yu Chen1,2, Kuo-Gon Wang1,3*, Tung-Yao Chang1, Chie-Pein Chen1, Jun-Hun Loo4
1Department of Obstetrics and Gynecology, Mackay Memorial Hospital, 2Mackay Medicine, Nursing and Management College,
3Taipei Medical University, and 4Transfusion Medicine Research Laboratory, Mackay Memorial Hospital, Taipei, Taiwan.
*Correspondence to: Dr. Kuo-Gon Wang, Department of Obstetrics
and Gynecology, Mackay Memorial Hospital, 92, Section 2,
Chung-Shan North Road, Taipei, Taiwan.
E-mail: aikuo7@ms15.hinet.net
Received: January 18, 2005
Revised: January 24, 2005
Accepted: January 26, 2005
Introduction
Antenatal corticosteroid administration is known to
reduce the incidence of respiratory distress syndrome
(RDS), intraventricular hemorrhage (IVH), periventri-
cular leukomalacia (PVL), and even necrotizing entero-
colitis (NEC) in preterm neonates [1–3]. However,
complications in neonates and mothers may occur
when antenatal corticosteroids are given, including
maternal or neonatal infection, sepsis, and maternal
pulmonary edema. The National Institutes of Health
(NIH) Consensus Development Conference recom-
mends treatment regimens of either two doses of 12 mg
of betamethasone given intramuscularly 24 hours apart
or four doses of 6 mg of dexamethasone given intra-
muscularly 12 hours apart between 24 and 34 weeks of
gestation in pregnancies at risk for preterm delivery [4].
The benefits are most apparent when the corticosteroids
are administered between 24 hours and 7 days before
SUMMARY
Objective: This study was undertaken to investigate the effects of antenatal betamethasone and dexamethasone
and to determine which is superior for preterm neonates.
Materials and Methods: This prospective, randomized, clinical investigation compared the effects of antenatal
betamethasone and dexamethasone in neonates born before 37 weeks of gestation between December 20,
2001 and September 10, 2003. Pregnant women with symptoms and signs of preterm labor at 24–34 weeks
of gestation or preterm premature rupture of membranes at 24–32 weeks of gestation were randomly divided
into two groups receiving either two 12-mg doses of betamethasone given intramuscularly 24 hours apart or
four 6-mg doses of dexamethasone given intramuscularly 12 hours apart. We compared the complications
of preterm neonates, such as respiratory distress syndrome (RDS), severe intraventricular hemorrhage (IVH),
periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), and
neonatal sepsis in the two groups.
Results: A total of 140 mothers were included in our study and 157 preterm neonates were surveyed, of whom
81 were exposed to antenatal betamethasone and 76 to antenatal dexamethasone. No significant differences
were found between the two groups in the incidence of RDS, severe IVH, PVL, NEC, ROP, and neonatal sepsis.
However, compared with a complete course of antenatal corticosteroids, the incidence of RDS was significantly
increased after an incomplete course (odds ratio, 2.48; 95% confidence interval, 1.04, 5.93; p = 0.04).
Conclusion: In our study, no significant differences between antenatal betamethasone and dexamethasone
were found in complications of preterm neonates. Incomplete courses of antenatal corticosteroids were
associated with an increased incidence of RDS compared with complete courses. [Taiwanese J Obstet Gynecol
2005;44(3):247–251]
Key Words: betamethasone, dexamethasone, intraventricular hemorrhage, necrotizing enterocolitis, neonatal
sepsis, periventricular leukomalacia, respiratory distress syndrome, retinopathy of prematurity
■  ORIGINAL ARTICLE  ■
C.Y. Chen, et al
Taiwanese J Obstet Gynecol • September 2005 • Vol 44 • No 3248
delivery. In principle, antenatal steroid therapy should
not be routinely repeated in patients with preterm
labor. For preterm premature rupture of membranes
(PPROM) at less than 30–32 weeks of gestation,
antenatal corticosteroids are also suggested as long as
there is no evidence of infection. Our study followed the
recommendations of the NIH consensus panel and
compared the complications in preterm neonates
between those exposed to antenatal betamethasone
and dexamethasone.
Materials and Methods
This prospective study was conducted at Mackay
Memorial Hospital between December 20, 2001 and
September 10, 2003. Pregnant women with symptoms
and signs of preterm labor between 24 and 34 weeks of
gestation or PPROM between 24 and 32 weeks of
gestation were admitted and included in the study.
These women were randomly divided into two groups,
receiving either two 12-mg doses of betamethasone
given intramuscularly 24 hours apart or four 6-mg doses
of dexamethasone given intramuscularly 12 hours apart.
Data were excluded for intrauterine fetal death,
immediate expiration after delivery, delivery after 37
weeks of gestation, or delivery not at our hospital, or if
no postnatal data were available. We compared
complications in the preterm neonates, including RDS,
severe IVH (grade 3 and 4), PVL, NEC, retinopathy of
prematurity (ROP), and neonatal sepsis. In addition,
infants from the two groups were compared for birth
weight, head circumference, and 5-minute Apgar score.
Differences in neonatal complications were compared
between incomplete and complete courses of antenatal
corticosteroids.
Preterm labor was diagnosed when persistent uterine
contractions 6–8 times/hour or four contractions in 20
minutes were accompanied by dilation and/or
effacement of the cervix detected via speculum
examination. PPROM was diagnosed in the presence of
a gush of fluid from the vagina followed by persistent,
uncontrolled leakage, or pooling of fluid on speculum
examination with positive nitrazine testing. The diagnosis
of RDS was based on a combination of clinical features
(tachypnea, nasal flaring, subcostal and intercostal
retractions, cyanosis, and an expiratory grunt), exclusion
of other causes of respiratory distress, and characteristic
radiographic appearance (a diffuse reticulogranular
pattern, giving the classic “ground-glass appearance”,
in both lung fields with superimposed air broncho-
grams). Cranial ultrasound was performed at least
twice to survey for IVH and PVL within the first week of
neonatal life and 6 weeks later. IVH was graded according
to severity of hemorrhage into the ventricular system;
grade 3 is IVH with ventricular dilatation and grade 4 is
IVH with associated parenchymal hemorrhage [5]. PVL
was defined as hyperechoic lesions (cysts or hollow
places) in the periventricular white matter. NEC was
diagnosed by clinical symptoms, physical examination,
and abdominal radiography. ROP was defined as the
abnormal growth of blood vessels within the retina and
vitreous humor and was diagnosed by ophthalmologic
examination. Neonatal sepsis was diagnosed from blood
or cerebrospinal cultures.
Statistical analysis was performed using Student’s t
test for continuous variables and the Chi-squared test
for categorical data. Fisher’s exact test was used to
examine neonatal complications numbering five or less.
Logistic regression was used to examine the influence of
incomplete courses of antenatal corticosteroids. A p
value of less than 0.05 was considered to be statistically
significant. For continuous variables, the results are
presented as mean ± standard deviation.
Results
During the study period, a total of 168 mothers received
antenatal corticosteroids. Fifteen delivered after 37 weeks
of gestation and eight delivered at other hospitals. One
intrauterine fetal death was noted, and four neonates
expired immediately after delivery so no postnatal data
were available. The remaining 140 mothers were included
in our study and 157 preterm neonates (17 sets of
twins) were surveyed, of whom 81 (51.6%) were exposed
to antenatal betamethasone and 76 (48.4%) to antenatal
dexamethasone. Mean maternal age was higher in the
betamethasone group (31.3 ± 5.3 vs 29.1 ± 5.5 years;
p = 0.01). No significant differences were noted between
the two groups with regard to gestational age at delivery,
parity, gender, multiplicity, mode of delivery, birth
weight, head circumference, and low 5-minute Apgar
score (Table 1). In addition, no statistically significant
differences were found between the two groups in the
incidence of RDS, severe IVH, PVL, NEC, ROP, and
neonatal sepsis (Table 2). Logistic regression adjusted
for gestational age showed that the incidence of RDS
was significantly increased after incomplete courses
of antenatal corticosteroids compared with complete
courses (odds ratio, OR, 2.48; 95% confidence inter-
val, CI, 1.04, 5.93; p = 0.04). There were no significant
differences in the incidence of severe IVH, PVL, NEC,
ROP, and neonatal sepsis between incomplete and
complete courses of antenatal corticosteroids (Table
3).
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Discussion
Preterm birth occurs in 7–10% of all pregnancies, and
complications of prematurity account for most perinatal
mortality and morbidity [4]. In the USA, prematurity-
related disorders cause more than 70% of fetal and
neonatal deaths [6]. Many randomized or controlled
trials have demonstrated that antenatal corticosteroids
reduce the risk of RDS, IVH, PVL, and even NEC of
premature infants [1–3]. Effects of antenatal
corticosteroids on the developing lung include increased
tissue and alveolar surfactant, increased compliance
and maximal lung volume, decreased vascular
permeability, more mature parenchymal structure,
enhanced clearance of lung water, enhanced response
to surfactant treatment, and improved respiratory
function [7]. Corticosteroids can also induce brain
germinal matrix microvasculature maturation and make
these vessels more resistant to rupture, thus decreasing
the risk of IVH [8,9]. The physiologic effects of antenatal
corticosteroid in PVL prevention include accelerated
cytodifferentiation, greater maturity of cerebrovascular
endothelial cells and autoregulation of cerebral
perfusion, and increased activity of antioxidant enzymes
[3]. Results vary in studies examining the effect of
antenatal steroid administration on the incidence of
NEC. Some conclude that antenatal corticosteroids
reduce the incidence because they consider that steroids
may accelerate intestinal maturation, but others
did not demonstrate a decreased risk [10–13]. The
Table 1. Perinatal characteristics
Betamethasone (n = 81) Dexamethasone (n = 76) p
Maternal age (yr)* 31.3 ± 5.3 29.1 ± 5.5 0.01
Gestational age (wk)* 31.2 ± 2.9 30.9 ± 3.2 0.59
Parity, n 1.68 1.45 0.23
Male infant, n (%) 43 (53.1) 42 (55.3) 0.91
Multiple pregnancy, n (%) 31 (38.3) 30 (39.5) 0.99
Cesarean delivery, n (%) 58 (71.6) 47 (61.8) 0.26
Birth weight (g)* 1,662 ± 578 1,613 ± 674 0.62
Head circumference (cm)* .28.7 ± 3.2 028.2 ± 3.5 0.35
5-min Apgar score < 7, n (%) 09 (11.1) 09 (11.8) 0.89
*Mean ± standard deviation.
Table 3. Neonatal complications according to completion of corticosteroid course
Incomplete course (n = 35) Complete course (n = 122) p
RDS, n 24 59 0.04
IVH (grade 3 or 4) , n 01 04 0.89
PVL, n 01 02 0.54
NEC, n 01 06 0.65
ROP, n 00 11 0.78
Neonatal sepsis, n 03 15 0.73
RDS = respiratory distress syndrome; IVH = intraventricular hemorrhage; PVL = periventricular leukomalacia; NEC = necrotizing enterocolitis; ROP = retinopathy
of prematurity.
Table 2. Neonatal complications according to corticosteroid treatment
Betamethasone (n = 81) Dexamethasone (n = 76) p
RDS, n (%) 44 (54.3) 39 (51.3) 0.64
IVH (grade 3 or 4) , n (%) 3 (3.7) 2 (2.6) 1.00
PVL, n (%) 1 (1.2) 2 (2.6) 0.62
NEC, n (%) 4 (4.9) 3 (3.9) 1.00
ROP, n (%) 6 (7.4) 5 (6.6) 0.96
Neonatal sepsis, n (%) 7 (8.6) 11 (14.5) 0.40
RDS = respiratory distress syndrome; IVH = intraventricular hemorrhage; PVL = periventricular leukomalacia; NEC = necrotizing enterocolitis; ROP = retinopathy
of prematurity.
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fluorinated steroids, betamethasone and dexa-
methasone, are generally the preferred corticosteroids
because of their beneficial effect on fetal organ devel-
opment. Both of these agents can cross the placenta
largely in biologically active form and have a long half-
life (3–5 hours) and duration of activity (36–54 hours),
identical biologic effects, little mineralocorticoid activity,
and relatively weak immunosuppressive activity [4].
They are almost identical in structure, differing only in
_ versus ` orientation of the methyl group at position
16. The dexamethasone regimen leads to a lower peak
level but a longer time to biologic activity and a rapid
passage through the blood–brain barrier compared
with the betamethasone regimen. Some reports reveal
that dexamethasone with sulfites may generate
neurotoxicity [14,15]. In 1994, the NIH recommended
either two 12-mg doses of betamethasone given
intramuscularly 24 hours apart or four 6-mg doses of
dexamethasone given intramuscularly 12 hours apart,
between 24 and 34 weeks of gestation [4]. Our study
compared the complications in preterm neonates
exposed to betamethasone or dexamethasone in the
antenatal period and found no significant difference
between the two groups in RDS, severe IVH (grade 3 and
4), PVL, NEC, ROP, and neonatal sepsis. Bar-Lev et al
carried out a retrospective study to assess the incidence
of short-term outcomes in 550 low birth weight infants
() 1,750 g) exposed prenatally to either betamethasone
or dexamethasone [16]. They also found no difference
in the incidence of premature complications. However,
Baud et al published a retrospective study of 883 infants
with gestational ages between 24 and 31 weeks and
found that betamethasone was associated with a lower
risk of PVL than dexamethasone [17]. Whitelaw and
Thoresen reviewed the literature and recommended
betamethasone rather than dexamethasone for the
immature brain [18]. Larger prospective clinical studies
and larger sample sizes are needed to obtain more
authoritative conclusions.
In our study, compared with complete courses of
antenatal corticosteroids, the incidence of RDS was
significantly increased in neonates exposed to incomplete
courses, and most of the mothers with incomplete
courses delivered within 24 hours after corticosteroid
administration. This finding is in agreement with the
NIH Consensus Statement, which considers that optimal
benefits of antenatal corticosteroids begin 24 hours
after initiation of therapy and last up to 7 days [4]. Most
neonates were exposed to an incomplete course of
antenatal corticosteroids due to imminent preterm
delivery. On the other hand, in a study to assess the
effectiveness between incomplete courses of antenatal
corticosteroids and no antenatal corticosteroids on
preterm perinatal outcomes, Elimian et al found that
even an incomplete course of antenatal corticosteroids
was associated with a reduction in the rate of IVH and
neonatal death [19]. It was suggested that even an
incomplete course of corticosteroid therapy should be
administered to a mother in danger of immediate
delivery.
In conclusion, our prospective study indicates that
there is no difference between antenatal betamethasone
and dexamethasone in the incidence of RDS, severe
IVH, PVL, NEC, ROP, and neonatal sepsis. It showed no
advantage with betamethasone over dexamethasone as
antenatal corticosteroid therapy in preterm neonates.
Further larger prospective clinical studies are necessary
to support our results. In addition, a complete course of
antenatal corticosteroids is better than an incomplete
course in decreasing the risk of RDS.
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